Gastric cancer remains a major cause of cancer-related mortality worldwide. The temporal
trends for this malignancy, however, are dynamic, and reports from the past decade indicate …

Epstein–Barr virus (EBV) is a ubiquitous human lymphotropic herpesvirus with a well-
established causal role in several cancers. Recent studies have provided compelling …

More than 1 million (1 089 103) new cases of gastric cancer were estimated globally in
2020, resulting in 768 793 deaths. 1 These burden estimates will continue to increase due to …

Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or
overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal …

Standard first-line chemotherapy results in disease progression and death within one year in
most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro …

Gastric cancer and gastro-oesophageal junction cancer represent a global health-care
challenge. Despite the efficacy of improved chemotherapy and surgical options, these …

The clinical use of molecular targeted therapy is rapidly evolving but has primarily focused
on genomic alterations. Transcriptomic analysis offers an opportunity to dissect the …

Despite neoadjuvant/conversion chemotherapy, the prognosis of cT4a/bN+ gastric cancer is
poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in …

Gastric cancer is not a top‐10 malignancy in the United States but represents one of the
most common causes of cancer death worldwide. Biological differences between tumors …

Background Evidence for the efficacy of combined PD-1 and HER2 blockade with
chemotherapy on progression-free and overall survival in HER2-positive gastro …